2021 Annual Meeting - Debating the Best Treatment for Early Prostate Cancer: Surgery, Radiation, or Neither
This session will involve a case-based discussion with a panel of experts to review the various treatment options for early stage prostate cancer, including active surveillance, radical prostatectomy, external beam radiotherapy (including intensity modulated radiation therapy and stereotactic body radiation therapy), brachytherapy, and proton beam therapy. Each modality will be discussed in the context of the impact on patient-centered quality of life.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, surgeons, nurses, radiation therapists and medical oncologists.
Upon completion of this activity, participants should be able to:
- Discuss the various treatment options for early stage prostate cancer.
- Explain the impact of active surveillance versus active treatment on patient quality of life and tumor control.
- Identify barriers to adopting newer treatment strategies for early stage prostate cancer.
- Rahul D. Tendulkar, MD, Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic and receives compensation from Varian Medical Systems.
- Andrew J Stephenson, MBA, MD, Rush University Medical Center and receives compensation from Exact Sciences.
- Alison Tree, MBBS, MD, The Royal Marsden NHS Foundation Trust and and receives compensation from Electa, Accuray, Janssen and Varian Medical Systems.
- Karen E. Hoffman, MD is employed Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center and receives compensation from from Janssen and Varian Medical Systems.
- Gerard Morton, MD, Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.